Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation

Summary

The main objective of this study is to assess the hemodynamic effects of sacubitril-valsartan in patients with heart failure with preserved ejection fraction and at least moderate atrial functional mitral regurgitation (AFMR), using a combination of cardiopulmonary exercise testing and stress echocardiography (referred to as CPETecho) at baseline and after six months of therapy. The patients included in this study will be randomly assigned to receive sacubitril-valsartan as an adjunct to standard medical care, as opposed to adhering solely to the standard of care which involves sodium-glucose cotransporter-2 (SGLT-2) inhibitor and mineralocorticoid receptor antagonist (MRA).

Timeline

Start

2024-02-29

Primary completion

2025-09-22

Completion

2026-05-09

Publications

• Dhont S, Moura Ferreira S, Galloo X, Martens P, Meekers E, Tartaglia K, Deferm S, Herbots L, Mullens W, Verbrugge FH, Verwerft J, Bertrand PB. Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: The PRAISE-MR Randomized Trial. Circulation. 2026 Jun 23;153(25):1973-1983. doi: 10.1161/CIRCULATIONAHA.126.080833. Epub 2026 May 9.

Drugs

Indications